gerenme/iStock by way of Getty Pictures
PDS Biotechnology Company (NASDAQ:PDSB) has been capable of make nice progress with respect to advancing using its lead candidate often called PDS0101, which is being developed together with Merck’s (MRK) Keytruda to deal with sure sufferers with HPV16-positive head and neck most cancers. The final time I spoke about this biotech it had not but launched interim information from this part 2 examine, nor talked about surpassing the efficacy threshold both. A key factor to notice concerning the interim evaluation was that 9 confirmed responses was achieved with 34 evaluable sufferers. Not solely that, however a brand new replace thereafter famous that the variety of confirmed responses elevated to 14. Thus, the efficacy threshold for Half 2 of this examine was achieved. With that stated, the plan is for PDS to submit an amended Investigational New Drug [IND] utility to the FDA in Q3 of 2023, because it prepares to provoke its part three VERSATILE-003 examine.
Versatile-002 Research Continues To Construct Momentum With Newly Up to date Knowledge
One key factor to notice is that PDS Biotechnology continues to construct proof that its drug PDS0101 given together with Keytruda in adults with HPV16-positive unresectable, recurrent or metastatic head and neck squamous cell carcinoma [HNSCC]. That is with respect to launched information, from the VERSATILE-002 examine, as a part of an ASCO poster presentation. The main focus of the presentation for this interim evaluation is predicated upon HNSCC sufferers who’re immune checkpoint inhibitor [ICI] remedy naive. That’s, sufferers who haven’t been beforehand handled with ICI remedy earlier than getting into this scientific examine. The interim information famous that the 12-month general survival [OS] fee was 87.1% and the median progression-free survival [PFS] fee was 10.Four months. A illness management fee [DCR] of 70.6% [24 out of 34 patients] was famous as nicely. Right now, the variety of confirmed responses was 9 out of 34 [26.5%]. Nonetheless, in June of 2023, this quantity modified, as presently it was said that 14 sufferers had a confirmed goal response.
Not solely was this a very good scientific replace as a result of the variety of confirmed goal response had elevated, but additionally for the truth that efficacy threshold was achieved. Once more, this was within the HPV16-positive unresectable, recurrent or metastatic HNSCC affected person inhabitants. The edge for efficacy, was obtained when 14 out of the 54 ICI naive sufferers enrolled achieved a confirmed goal response. The explanation why I really feel that this newly up to date information was necessary to focus on is as a result of the efficacy threshold was reached, when many extra sufferers haven’t but undergone imaging analysis. It is crucial for these sufferers to endure imaging analysis to be thought-about as having a confirmed goal response. Thus, as extra sufferers endure such an analysis, then it is attainable that extra sufferers may later be labeled as having a confirmed goal response. This isn’t assured to occur, however extremely attainable. With all of the optimistic information in hand, PDS expects to submit an amended Investigational New Drug [IND] utility to the FDA in Q3 of 2023. The explanation for doing so is to have the ability to ultimately provoke its part three VERSATILE-003 examine, which goes to make use of PDS0101 together with Keytruda to deal with sufferers with HPV16-positive HNSCC.
Financials
In line with the 10-Q SEC Submitting, PDS Biotechnology had money and money equivalents of roughly $65.2 million as of March 31, 2023. It believes that this will likely be sufficient money to fund its operations into Q3 of 2024. Nonetheless, it has been capable of elevate money by different means. I am speaking about an “At Market Issuance Gross sales Settlement, or the Gross sales Settlement, with B. Riley Securities, Inc. and BTIG, LLC as nicely. This was an settlement made with each firms by which PDS Biotech may provide and promote, now and again at its sole discretion, shares of its frequent inventory with an mixture providing worth of as much as $50 million. For the 12 months ending December 31, 2022 it offered 1,238,491 shares of its frequent inventory which helped it to boost $9.9 million. Then, within the quarter ending March 31st 2023, it offered 553,293 shares of its frequent inventory that helped it to boost roughly $4.6 million pursuant to the Gross sales Settlement.
Dangers To Enterprise
There are a number of dangers that buyers ought to pay attention to earlier than investing in PDS Biotechnology. The primary danger to contemplate can be with respect to the development of the quickly to be initiated part three VERSATILE-003, which is utilizing PDS0101 together with Keytruda to deal with sufferers with HPV16-positive head and neck squamous cell carcinoma [HNSCC]. That is as a result of with the part three being initiated in late 2023, it might be just a few years earlier than information is launched from it for starters. Secondly, despite the fact that this biotech was capable of get hold of optimistic outcomes from the part 2 VERSATILE-002 examine in fewer sufferers, there isn’t any assure that comparable or superior outcomes will likely be obtained upon trial information being launched for VERSATILE-003. A second danger to contemplate can be the monetary place that this firm is in. That is as a result of it believes that it has sufficient money to fund its operations into Q3 of 2024. With this being about one-year price of money, it’s extremely probably that it could must enact a money elevate quickly. Within the meantime, it has been promoting some shares from its ATM settlement as I famous above.
Conclusion
The ultimate conclusion is that PDS Biotech is an effective speculative biotech play to look into. That is as a result of it’s gearing as much as provoke its part three VERSATILE-003 examine, which is utilizing PDS0101 together with Keytruda to deal with HPV16-positive HNSCC sufferers. An amended protocol, which the biotech expects to submit in Q3 of 2023, will permit to provoke such a part three examine. The HNSCC market is a big one and it’s nonetheless an enormous unmet medical want. The pinnacle and neck most cancers market is anticipated to achieve $9.07 billion by 2030. It is a large market alternative and if PDS can ultimately get hold of FDA approval of PDS0101 for the therapy of this affected person inhabitants, then it is going to be in fine condition to go after it.